NVS

Novartis AG Form 6-K Summary: First Nine Months 2009

Business Context and Reporting Period

This Form 6-K, dated October 22, 2009, reports the financial results for Novartis AG for the nine-month period ended September 30, 2009, and the third quarter of 2009. The Swiss-based pharmaceutical company operates through four primary divisions: Pharmaceuticals, Vaccines and Diagnostics, Sandoz (generics), and Consumer Health. The reporting period highlights strong underlying growth in the healthcare portfolio, driven by new product momentum, despite headwinds from currency fluctuations and specific non-operating charges.

Key Financial Metrics

Material Changes vs. Prior Period

• Currency Impact: A stronger US dollar offset underlying business expansion, resulting in flat reported net sales despite an 8% increase in local currencies. Currency movements negatively impacted reported results by approximately 8 percentage points.
• Net Income Decline: Reported net income fell 8% due to Alcon-related financing costs, a higher tax rate (15.2% vs. 14.0%), and a significant reduction in income from associated companies (Roche and Alcon) totaling $189 million in charges.
• Divisional Performance:
  • Pharmaceuticals: Net sales rose 11% in local currencies, driven by double-digit growth in all regions and new products (e.g., Afinitor, Lucentis, Exforge).
  • Vaccines and Diagnostics: Sales declined 13% in local currencies due to lower H5N1 avian flu vaccine sales, though H1N1 pandemic vaccine deliveries began in late September.
  • Sandoz: Achieved 4% local currency growth, with a turnaround in the US market.
• Balance Sheet: Total assets increased to $90.7 billion, and equity rose to $53.3 billion. The debt-to-equity ratio increased to 0.27:1 following bond issuances, but net debt was significantly reduced to $0.2 billion.

Guidance, Outlook, and Risks

• Outlook: Management expects record full-year underlying results in constant currencies for 2009. Group net sales are projected to grow at a high-single-digit rate in local currencies, with Pharmaceuticals expected to expand at a double-digit rate.
• Key Drivers: Continued momentum from new product launches (Afinitor, Ilaris, H1N1 vaccines) and productivity gains. The H1N1 vaccine program is expected to contribute $400 million to $700 million in Q4 net sales.
• Risks and Contingencies:
  • Legal Proceedings: Ongoing investigations regarding off-label marketing (Trileptal, Diovan, etc.) and product liability litigation (Zometa/Aredia, Zelnorm). A $72.5 million settlement was reached regarding TOBI marketing.
  • Regulatory: Uncertainties regarding clinical trial results and regulatory approvals for pipeline products (e.g., FTY720, QAB149).
  • Financial: Currency volatility remains a significant risk to reported results. Interest expenses rose 85% YTD due to new bond issuances.

Investor Verification Checklist

• Verify the sustainability of the 11% local currency growth in the Pharmaceuticals division as new products mature.
• Monitor the impact of the $189 million charge from associated companies (Roche/Alcon) on future earnings from these investments.
• Assess the progress of the H1N1 vaccine rollout and its actual contribution to Q4 revenue versus the $400M-$700M estimate.
• Review the status of ongoing legal investigations, particularly the Trileptal and Zometa cases, for potential future liabilities.
• Track the integration and performance of the EBEWE Pharma injectables acquisition ($1.2 billion) in the Sandoz division.